Disease severity and clinical outcomes of community acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicenter prospective registry study from CAP-China Network

By Fei Zhou, Yimin Wang, Yingmei Liu, Xuedong Liu, Li Gu, Xiaoju Zhang, Zenghui Pu, Guoru Yang, Bo Liu, Qingrong Nie, Bing Xue, Jing Feng, Qiang Guo, Jianhua Liu, Hong Fan, Jin Chen, Yongxiang Zhang, Zhenyang Xu, Min Pang, Yu Chen, Xiuhong Nie, Zhigang Cai, Jinfu Xu, Kun Peng, Xiangxin Li, Pingchao Xiang, Zuoqing Zhang, Shujuan Jiang, Xin Su, Jie Zhang, Yanming Li, Xiuhong Jin, Rongmeng Jiang, Jianping Dong, Yuanlin Song, Hong Zhou, Chen Wang, Bin Cao CAP-China network

European Respiratory Journal, June 4, 2019

 

Although a wide knowledge of influenza viral pneumonia have been established, the significance of non-influenza respiratory viruses in community acquired pneumonia (CAP) and their impact on clinical outcomes remains unclear, especially in non-immunocompromised adult population. Hospitalised immunocompetent patients with CAP were prospectively recruited from 34 hospitals in Mainland China. Respiratory viruses were detected by molecular methods. Comparisons were conducted between influenza and non-influenza viral-infection groups. In total, 915 of 2336 adult patients with viral infection were enrolled in the analysis with influenza virus (28.4%) most frequently detected, followed by respiratory syncytial virus (3.6%), adenovirus (3.3%), human coronavirus (3.0%), parainfluenza virus (2.2%), human rhinovirus (1.8%), and human metapneumovirus (1.5%). Non-influenza viral infections accounted for 27.4% of viral pneumonia. Consolidation was more frequently observed in patients with adenovirus infection. The occurrence of complications such as sepsis (40.1% versus 39.6%, p=0.890) and hypoxemia (40.1% versus 37.2%, p=0.449) during hospitalisation in influenza group didn't differ from that of non-influenza group. Compared with influenza viral infection, the multivariable-adjusted odds ratios and 95% confidence intervals (CIs) of CURB-65 >3, PaO2/FiO2 <200 mmHg, and occurrence of sepsis or hypoxemia for non-influenza viral infection were 0.87 (0.26-2.84), 0.72 (0.26-1.98), 1.00 (1.63-1.58), and 1.05 (0.66-1.65), respectively. The hazard ratio and 95% CI of 90-day mortality was 0.51 (0.13-1.91). The high incidence of complications in non-influenza viral pneumonia and similar impact of non-influenza viruses relative to influenza virus on disease severity and outcomes suggest more attention should be given to CAP caused by non-influenza viruses.

Access article here

8 Hits
0 Comments

Predictors of ‘unlikely bacterial pneumonia’ and ‘adverse pneumonia outcome’ in children admitted to hospital in central Vietnam

By Phuong T K Nguyen, Hoang T Tran, Thach S Tran, Dominic A Fitzgerald, Stephen M Graham, Ben J Marais

Clinical Infectious Diseases, May 27, 2019

 

Prospective enrolment of all children under five admitted with ‘pneumonia’ (per clinician assessment) to the Da Nang Hospital for Women and Children over a one-year period. Children were classified as having ‘likely or ‘unlikely’ bacterial pneumonia and followed for outcome assessment. A Bayesian Model Averaging (BMA) approach was used to identify predictors of ‘unlikely bacterial pneumonia’ and ‘adverse pneumonia outcome’, which guided the development of a pragmatic management algorithm.

Of 3,817 patients assessed, 2,199 (57.6%) met World Health Organisation (WHO) pneumonia criteria. In total, 1594 (41.7%) children were classified as ‘unlikely’ and 129 (3.4%) as ‘likely’ bacterial pneumonia. The remainder (2,399; 62.9%) were considered to have disease of ‘uncertain aetiology’. Factors predictive of ‘unlikely bacterial pneumonia’ were ‘no fever’, ‘no consolidation on chest radiograph’ and ‘absolute neutrophil count <5x109/L’ at presentation, which had a negative predictive value (NPV) for ‘likely bacterial pneumonia’ of 99.0%. Among those meeting WHO pneumonia criteria 8.6% (189/2,199) experienced an adverse outcome. Not having ‘any WHO danger sign’ or ‘consolidation on chest radiograph’ had a NPV of 96.8% for ‘adverse pneumonia outcome’.

Continue reading
3 Hits
0 Comments

Atypical and Typical Bacteria in Children with Community Acquired Pneumonia

Jama-Kmiecik A, Frej-Mądrzak M, Sarowska J, Teryks-Wołyniec D, Skiba A, Choroszy-Król  

 

Part of the Advances in Experimental Medicine and Biology book series, April 2019

 

This seeks to determine the pathogens in respiratory specimens and blood serum obtained from children who present with community acquired pneumonia (CAP) diagnosed on the basis of clinical and radiological evidence. The study group consisted of 46 hospitalized children aged 1–11 years. The material for research consisted of pharyngeal swabs and samples of blood serum. One hundred and thirty eight pharyngeal swabs were examined for the presence of C. pneumoniae antigen, C. pneumoniae DNA, and for typical pathogens. C. pneumoniae DNA was detected in pharyngeal swabs with nested PCR. Classical microbiological culture was used for detection of typical bacteria. ELISA test were used for detection anti-C. pneumoniae and anti-M. pneumoniae antibodies in the serum. C. pneumoniae DNA was identified in 10.9% of children. Positive culture for typical pathogens was observed in 8.7% of children. Specific anti-C. pneumoniae IgM antibodies were found in 8.7% of children, and IgG and IgA antibodies in 1 child each. Specific anti-M. pneumoniae IgG antibodies were found in 13.1% of children and IgM antibodies in 1 child. We conclude that the underlying bacterial etiology of CAP is rather rarely conclusively confirmed in children. Nonetheless, determining the etiology of CAP is essential for the choice of treatment to optimize the use and effectiveness of antimicrobials and to avoid adverse effect. Due to considerable variations in the power of detection of the type of atypical bacteria causing CAP, the search for the optimum diagnostic methods continues.

Continue reading
36 Hits
0 Comments

Association between urinary community-acquired fluoroquinolone-resistant Escherichia coli and neighbourhood antibiotic consumption: a population-based case-control study

by Marcelo Low, MPH; Ami Neuberger, MD; Prof Thomas M Hooton, MD; Prof Manfred S Green, MBChB; Prof Raul Raz, MD; Prof Ran D Balicer, MD; et al.

Published in The Lancet Infectious Diseases, 01 April 2019. 

 

 

It is unknown whether increased use of antibiotics in a community increases the risk of acquiring antibiotic resistance by individuals living in that community, regardless of prior individual antibiotic consumption and other risk factors for antibiotic resistance. Researchers used a hierarchical multivariate logistic regression approach to evaluate the association between neighbourhood fluoroquinolone consumption and individual risk of colonisation or infection of the urinary tract with fluoroquinolone-resistant Escherichia coli. A population-based case-control study of adults (aged ≥22 years) living in 1733 predefined geographical statistical areas (neighbourhoods) in Israel was performed. A multilevel study design was used to analyse data derived from electronic medical records of patients enrolled in the Clalit state-mandated health service. 300,105 events with E coli growth and 1 899 168 cultures with no growth were identified from medical records and included in the analysis. 45 427 (16·8%) of 270 190 women and 8835 (29·5%) of 29 915 men had fluoroquinolone-resistant E coli events. The study team found an independent association between residence in a neighbourhood with higher antibiotic consumption and an increased risk of bacteriuria caused by fluoroquinolone-resistant E coli. Odds ratios (ORs) for the quintiles with higher neighbourhood consumption (compared with the lowest quintile) were 1·15 (95% CI 1·06–1·24), 1·31 (1·20–1·43), 1·41 (1·29–1·54), and 1·51 (1·38–1·65) for women, and 1·17 (1·02–1·35), 1·24 (1·06–1·45), 1·35 (1·15–1·59), and 1·50 (1·26–1·77) for men. Results remained significant when the analysis was restricted to patients who had not consumed fluoroquinolones themselves. These data suggest that increased use of antibiotics in specific geographical areas is associated with an increased personal risk of acquiring antibiotic-resistant bacteria, independent of personal history of antibiotic consumption and other known risk factors for antimicrobial resistance.  Article access can be found here.   
55 Hits
0 Comments

Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial

by Daan Barug, MD; Inge Pronk, BSc; Marlies A van Houten, MD; Florens G A Versteegh, PhD; Mirjam J Knol, PhD; Jan van de Kassteele, PhD; et al.

Published in The Lancet Infectious Diseases, 01 April 2019.

 

Maternal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination offers protection for neonates against clinical pertussis until primary vaccinations, but maternal antibodies also interfere with infants' immune responses to primary vaccinations. Researchers investigated the effect of maternal Tdap vaccination on the pertussis antibody responses of infants starting primary vaccinations at age 3 months. In an open-label, parallel, randomised, controlled trial, pregnant women aged 18–40 years with a low risk of pregnancy complications were recruited through independent midwives at 36 midwife clinics in the Netherlands and received Tdap vaccination either at 30–32 weeks of pregnancy (maternal Tdap group) or within 48 h after delivery (control group). All term-born infants were vaccinated with the diphtheria, tetanus, and pertussis-inactivated poliomyelitis- Haemophilus influenzae type B-hepatitis B six-in-one vaccine and a ten-valent pneumococcal vaccine at 3 months, 5 months, and 11 months. Randomisation was done using a number generator in a 1:1 ratio and with sealed envelopes. Participants and clinical trial staff were not masked, but laboratory technicians were unaware of study group assignments. The primary endpoint was serum IgG pertussis toxin antibody concentrations at age 3 months. Cord blood and infant blood samples were collected at age 2 months, 3 months, 6 months, 11 months, and 12 months. Analysis was done by modified intention to treat with all randomly assigned participants in case a laboratory result was available. This trial is registered with ClinicaltTrialsRegister.eu (EudraCT 2012-004006-9) and trialregister.nl (NTR number NTR4314). The trial is now closed to new participants. Between Jan 16, 2014, and March 4, 2016, 118 pregnant women were enrolled into our study, with 58 in the maternal Tdap group and 60 in the control group. The geometric mean concentration (GMC) of pertussis toxin antibodies were higher in infants in the maternal Tdap group than in the control group infants at age 3 months (GMC ratio 16.6, 95% CI 10.9–25.2) and also significantly higher compared with control infants at age 2 months. After primary vaccinations, antibody concentrations for pertussis toxin, filamentous haemagglutinin, and pertactin were significantly lower at all time points in infants of the maternal Tdap group than in infants in the control group. No safety issues after maternal Tdap vaccination were encountered. In view of the high pertussis toxin antibody concentrations at age 3 months, maternal vaccination supports a delay of the first pertussis vaccination in infants until at least age 3 months. Maternal antibody interference affects antibody concentrations after primary and booster vaccinations. The clinical consequences of this interference remain to be established.  Article access can be found here.    
57 Hits
0 Comments

Longitudinally evaluating the lung function of children in low- and middle-income countries: it's about time

by Eric D McCollum

Published in Clinical Infectious Diseases, 28 March 2019. 

 

Article access can be found here. 

 

Continue reading
60 Hits
0 Comments

Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study

by Picazo JJ, Ruiz-Contreras J, Casado-Flores J, Negreira S, Baquero-Artigao F, Hernández-Sampelayo T, Otheo E, Amo MD, Méndez C; Heracles Study Group

Published in Vaccine, 19 March 2019.

 

 

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide. Using the data from the HERACLES clinical surveillance study (2007-2016), researchers describe the population impact of the 13-valent pneumococcal conjugate vaccine (PVC13) on invasive pneumococcal disease (IPD) in children <15 years of age in the Community of Madrid, Spain.

Continue reading
43 Hits
0 Comments

Ongoing Exposure of U.K. Infants to Vaccine Serotype Pneumococci

by Mary Slack, FRCPATH; Andrew Vyse, PhD; Harish Madhava, MD; Ralf-Rene Reinert, MD; Gillian Ellsbury, MD; Carole Czudek, PhD; Bradford Gessner, MD

Published in The Pediatric Infectious Disease Journal, April 2019. doi: 10.1097/INF.0000000000002184  "To the editors: 

We read with interest the article by Makwana et al. The authors note that most childhood invasive pneumococcal disease (IPD) cases are now due to non-13 valent pneumococcal conjugate vaccine (PCV13) serotypes though PCV13 serotypes remain in circulation with serotypes 3 and 19A listed among the top 10 that caused IPD in children in 2015/16. Of the 25 cases with PCV13-type IPD in 2015/16, 11 (44%) were due to serotype 19A.

 

Key insight is given into the IPD burden in infants 3–11 months of age, which over the 6-year study period accounted for a substantial proportion (508/1255, 40%) of the total in children <5 years of age. Additionally, meningitis was most prevalent in infants (209/456 cases, 45.8%) and was associated with the highest case fatality (9.6%). The most recent data from 2015/16 showed 103/271 (38%) of IPD cases occurred in infants 3–11 months of age, with 5 (4.8%) attributed to PCV13 serotypes. This reflects an increase in infant IPD compared with 2014/15 and slightly exceeds the number of cases in this age group in 2010/11 when PCV13 was first introduced illustrating a continuing and substantial burden of infant IPD. ..."

 

Continue reading
60 Hits
0 Comments

Respiratory syncytial virus (RSV) and child pneumonia

RSV-and-child-pneumonia-webinar-cover-im_20190314-164122_1

Above, photo submitted by Keith Klugman, The Bill & Melinda Gates Foundation

 

Talks by:

 

Ting Shi, University of Edinburgh: ”Global disease burden estimate of RSV in young children”

 

Continue reading
204 Hits
0 Comments

Influenza and child pneumonia

InfluenzaA-img-KTalaat-presentation

Above, photo submitted by Kawsar Talaat, Johns Hopkins Bloomberg School of Public Health

 

 

Talks by:

Tim Uyeki (Influenza Division, Centers for Disease Control and Prevention): “Influenza and Influenza-associated Pneumonia in Children”

 

Continue reading
130 Hits
0 Comments

Epidemiological characteristics of nasopharyngeal Streptococcus pneumoniae strains among children with pneumonia in Chongqing, China

by YY Yu, XH Xie, Y Deng, Y Gao, Y Zhang, H Li, J Luo, ZX Luo, and EM Liu

Published in Scientific Reports, 01 March. 2019. doi: 10.1038/s41598-019-40088-6

 

 

Streptococcus pneumoniae (pneumococcus) is the most common respiratory pathogen worldwide. Nasopharyngeal carriage with S. pneumoniae is the major source of lower respiratory tract infection and horizontal spread among children. Investigating nasopharyngeal S. pneumoniae is crucial for clinicians to control pneumococcus disease. Researchers retrospectively analyzed clinical information of 5,960 hospitalized children, focusing on pneumonia children less than five years with positive nasopharyngeal pneumococcal cultures. Nasopharyngeal aspirates (NPAs) were collected between June 2009 and December 2016, which were outside the pneumococcal conjugate vaccine (PCV) period. NPAs were subjected to common bacterial culture and antibiotic susceptibility tests, and serotypes were identified by both multiplex PCR and DNA sequencing. Results clearly revealed that clinical manifestations of the children whose NPAs were S. pneumoniae culture positive were serious, especially in those less than twelve months old. Fifteen different serotypes of nasopharyngeal S. pneumoniae were detected, the most common ones being 19F (35.2%), 6A/B (23.8%), 19A (11.4%), 15B/C (9.3%) and 23F (7.8%). Eight serotypes, accounting for 85.5% of the isolates, corresponded to the PCV13 serotypes. Approximately one-third of all S. pneumoniae strains were susceptible to penicillin. Overall, researchers consider nasopharyngeal S. pneumoniae culture as beneficial in assessing the situations of pneumonia children. Moreover, PCV13 could be useful in preventing pneumococcal disease in Chongqing, China.

Continue reading
64 Hits
0 Comments

Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: a data linkage modelling study

by RM Reeves, P Hardelid, N Panagiotopoulos, M Minaji, F Warburton, and R Pebody

Published in The Journal of Infection, 25 February 2019. doi: 10.1016/j.jinf.2019.02.012

 

 

Current national estimates of respiratory syncytial virus (RSV)-associated hospital admissions are insufficiently detailed to determine optimal vaccination strategies for RSV. Researchers employed novel methodology to estimate the burden of RSV-associated hospital admissions in infants in England, with detailed stratification by patient and clinical characteristics.

Continue reading
53 Hits
0 Comments

Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial

by Alistair Story, PhD; Robert W Aldridge, PhD; Catherine M Smith, PhD; Elizabeth Garber, MSc; Joe Hall, MSc; Gloria Ferenando, MSc; et al.

Published in The Lancet, 21 February 2019. DOI: https://doi.org/10.1016/S0140-6736(18)32993-3

 

 

Directly observed treatment (DOT) has been the standard of care for tuberculosis since the early 1990s, but it is inconvenient for patients and service providers. Video-observed therapy (VOT) has been conditionally recommended by WHO as an alternative to DOT. Researchers tested whether levels of treatment observation were improved with VOT.

Continue reading
61 Hits
0 Comments

Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children

by Naïm Ouldali, MD; Corinne Levy, MD; Philippe Minodier, MD; Laurence Morin, MD; Sandra Biscardi, MD; Marie Aurel, MD; François Dubos, PhD; Marie Alliette Dommergues, PhD; Ellia Mezgueldi, MD; Karine Levieux, MD; Fouad Madhi, MD; Laure Hees, MD; Irina Craiu, MD; Chrystèle Gras Le Guen, PhD; Elise Launay, PhD; Ferielle Zenkhri, MD; Mathie Lorrot, PhD; Yves Gillet, PhD; Stéphane Béchet, MSc; Isabelle Hau, MD; Alain Martinot, MD; Emmanuelle Varon, MD; François Angoulvant, PhD; and Robert Cohen, MD

Published in JAMA Pediatrics 04 February 2019. doi:10.1001/jamapediatrics.2018.5273

 

 

In several countries, 5 years after 13-valent pneumococcal conjugate vaccine (PCV13) implementation, serotype replacement has been reported for invasive pneumococcal disease, which raises concerns about the long-term outcome of PCV13 implementation. The long-term effect of vaccination on community-acquired pneumonia (CAP) remains unknown. This study aimed to assess the long-term outcome of PCV13 implementation on CAP in children.

Continue reading
115 Hits
0 Comments

Modifiable risk factors for community-acquired pneumonia in children under 5 years of age in resource-poor settings: a case-control study

by Ngocho JS, de Jonge MI, Minja L, Olomi GA, Mahande MJ, Msuya SE, and Mmbaga BT

Published in Tropical Medicine & International Health, 31 January 2019. doi: 10.1111/tmi.13211

 

 

Despite the availability of vaccines and antibiotics, pneumonia remains the leading cause of mortality among children under 5 years of age. The objective of this study was to identify modifiable risk factors for community-acquired pneumonia (CAP) in children under 5 years of age in a vaccinated population.

Continue reading
51 Hits
0 Comments

Bacteremic Community-Acquired Pneumonia in Ethiopian Children: Etiology, Antibiotic Resistance, Risk Factors, and Clinical Outcome

By Abel Abera Negash, Daniel Asrat, Workeabeba Abebe, Tewodros Hailemariam Tsegaye Hailu, Abraham Aseffa, Mario Vaneechoutte

 

Open Forum Infectious Diseases, January 2019

 

Community-acquired pneumonia (CAP) remains a leading cause of morbidity and mortality. We sought to determine the magnitude, etiology, and risk factors of CAP in children 5 years after introduction of pneumococcal conjugate vaccine (PCV) 10 in Ethiopia..

Continue reading
22 Hits
0 Comments

Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness

by Adrienne G Randolph, Ruifei Xu, Tanya Novak, Margaret M Newhams, Juliane Bubeck Wardenburg, Scott L Weiss, Ronald C Sanders, Neal J Thomas, Mark W Hall, Keiko M Tarquinio, Natalie Cvijanovich, Rainer G Gedeit, Edward J Truemper, Barry Markovitz, Mary E Hartman, Kate G Ackerman, John S Giuliano, Jr, Steven L Shein, Kristin L Moffitt, Pediatric Intensive Care Influenza Investigators from the Pediatric Acute Lung Injury and Sepsis Investigator’s Network

Published in Clinical Infectious Diseases, 18 January 2019

 

 

Coinfection with influenza virus and methicillin-resistant Staphylococcus aureus (MRSA) causes life-threatening necrotizing pneumonia in children. Sporadic incidence precludes evaluation of antimicrobial efficacy. Researchers assessed the clinical characteristics and outcomes of critically ill children with influenza–MRSA pneumonia and evaluated antibiotic use. Researchers enrolled children (<18 years) with influenza infection and respiratory failure across 34 pediatric intensive care units 11/2008–5/2016. Baseline characteristics, clinical courses, and therapies in children with MRSA coinfection, non-MRSA bacterial coinfection, and no bacterial coinfection were compared. The study found that influenza–MRSA coinfection is associated with high fatality in critically ill children. These data support early addition of a second anti-MRSA antibiotic to vancomycin in suspected severe cases.

Continue reading
93 Hits
0 Comments

Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany

by Stephanie Perniciaro, Matthias Imöhl, Christina Fitzner, and Mark van der Linden

Published in PLOS One, 09 January 2019. https://doi.org/10.1371/journal.pone.0210278

 

 

Invasive pneumococcal disease (IPD) is responsible for nearly half a million deaths per year in children under five, and also represents 5% of all-cause child mortality. The German National Reference Center for Streptococci (GNRCS) has been collecting invasive pneumococcal isolates from children since 1997. Disease surveillance on pediatric IPD is ongoing throughout the world, with a notable uptick following the development of pneumococcal conjugate vaccines (PCVs), which are a common component of childhood immunization programs.

Continue reading
77 Hits
0 Comments

Late-Career Physicians Prescribe Longer Courses of Antibiotics

by Cesar I Fernandez-Lazaro, Kevin A Brown, Bradley J Langford, Nick Daneman, Gary Garber, and Kevin L Schwartz

Published in Clinical Infectious Diseases, 07 January 2019. https://doi.org/10.1093/cid/ciy1130

 

 

Antibiotic duration is often longer than necessary. Understanding the reasons for variability in antibiotic duration can inform interventions to reduce prolonged antibiotic use. Here, researchers aim to describe patterns of inter-physician variability in prescribed antibiotic treatment durations and determine physician predictors of prolonged antibiotic duration in the community setting.

Continue reading
99 Hits
0 Comments

Community case management of lower chest indrawing pneumonia with oral amoxicillin in children in Kenya

by Onono M, Abdi M, Mutai K, Asadhi E, Nyamai R, Okoth P, and Qazi SA.

Published in Acta Paediatrica, December 2018. doi: 10.1111/apa.14405

 

 

The aim of this study was to determine the accuracy and effectiveness of community health workers (CHWs) when compared to trained nurses for management of pneumonia in Kenyan children.

Continue reading
109 Hits
0 Comments